China's State FDA hit by probe of another top official
This article was originally published in Scrip
The deputy director of China's State Food and Drug Administration (SFDA) has been dismissed from his position for unspecified suspected "disciplinary violations".
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.